Eric Lefkofsky Startup Tempus, On Improving Cancer Treatments

Tempus CEO and philanthropist have been in the line of improving data management of Cancer through technology, a venture that was more than necessary. The billionaire was recently captioned saying that he is willing to invest over $100 million in Tempus to realize its mission. Tempus Company is focused on saving the lives of cancer patients through customized cancer treatments using genomic sequencing.

Tempus has raised a total funding of $130 million since it began in the year 2015. The current estimate valuation of Tempus is said to be at approximately $700 million though Eric Lefkofsky has not confirmed this information. Co-founder Brad Keywell and Lefkofsky remain the largest individual investors in Tempus. The company continues to add on investors and also receives funding New Enterprise Associates and Revolution Growth. The loss of a loved one motivated Lefkofsky venture into health. Tempus has so far made partnerships with the Mayo Clinic, The Cleveland Clinic, and the Duke University School of Medicine among others.

Eric Lefkosky has founded and co-founded some successful companies. Among his currently trading corporations are Echo Global Logistics, MediaBank, Groupon.com and the new Tempus. Among the groups that have made tremendous success include Groupon.com which was announced as the fastest growing company by Forbes. Eric still maintains his position as the Chairman of Groupon.com after stepping down as CEO.

Lefkofsky is on the board of directors of various institutions which include The Art institution of Chicago, The Museum of Science and Industry, Children Memorial Hospital and World Business Chicago. He is also a trustee of Steppenwolf Theater Company. He was also involved in the committee that was responsible for the 206 summer Olympics in Chicago. Lefkofsky has also been involved in philanthropic work. In 2006, He, together with His wife Elizabeth founded The Lefkofsky foundation which primary focus is on children. The foundation has funded over 50 organizations so far and continued to so. The Lefkofskys also joined the Giving Pledge in 2013. Lefkofsky hopes to help in saving for more cancer patients through Tempus. He is positive about the company moving its agenda on a global scale.

Oncotarget Publishes Findings on The Use of miR-31-3p Expression

IntegraGen is a company that specializes in the conversion of sensitive data from the raw biological forms into genomic data in addition to diagnostic tools made for oncology. The company just announced that the search results of an analysis report concerning miR-31-3p expression are in Oncotarget. The publishing is a step forward towards finding treatment for tumor expressed diseases. The title of the article reads Association between miR-31-3p. The publication is a confirmation of good analysis on miR-31-3p expression levels. The patients with RAS type of wild metastatic cancer can be utilized to conduct diagnostic tool with the aim of identifying patients that will benefit from the tests.

Profile of Research

The peer-reviewed article that was published is a huge contribution towards the evidence –based research on the benefits of miR-31-3p tumors that originate from patients who have metastatic colorectal cancer. According to Mr. Yann Gaston-Mathe, the director in charge of Molecular Diagnostic, the publication of the research findings is a step towards accomplishing the benefits of precision in medicine.

Oncotarget Features Cancer Treatment

Colorectal cancer is the world’s third common cancer found in men. In women, it ranks second. Research has been conducted to find viable treatment for this cancer. The therapies have been put in place to deliver the right information to doctors. Oncotarget just featured an article on the latest treatment therapy. That is why Oncotarget is highly regarded. The scientific journal seeks to share vital data concerning treatment and the new research in different sectors of medicine. As a scientific journal that shares information, Oncotarget is published twice in a week. In other scenarios, it can be printed when a demand is made.

Conclusion

Oncotarget has always featured articles based on the seriousness of the content. The panel in charge of editing and publishing is well versed with the requirements that must be met. Oncotarget is manned by Mikhail Blagosklonny, a research scientist. His great leadership has been helpful in growing the data base of the journal. Most medical practitioners are turning to the journal to seek vital data. Through Oncotarget, medical practitioners have found a medium through which they can share vital data on treatment.

The Outstanding Oncology Research of Mikhail Blagosklonny

Mikhail Blagosklonny is a revered New York-based professor of oncology who has made significant contributions in cancer treatment. He currently works at the Buffalo-based Rosewell Park Cancer Institute and has done a lot of research about cancer therapies. Blagosklonny also works at Oncotarget where he is the editor-in-chief and has published a lot of research work that focuses on aging. He is recognized for promoting the use of a cancer drug that is called Rapamycin. He believes that the cure can significantly increase the lives of cancer patients. The professor has made great accomplishments during his career life. Rapamycin is a drug that was formed to prevent rejections during organ transplants. It is also known as Sirolimus. Other uses of the drug include curing a rare lung disease, hemolytic-uremic syndrome, lymphangioleiomyomatosis (LAM), facial angiofibromas, tuberous sclerosis complex (TSC), and coating coronary stents. Its trade name in the pharmaceuticals world is Rapamune and is recognized as a cancer drug. Rapamycin was first created in 1972 from bacteria samples that were discovered on Eastern Island. It was first used as an anti-fungal agent before scientists found out that it had antiproliferative and immunosuppressive properties.

Blagosklonny has been working to ensure that cancer patients get the best cures since he believes that human life is valuable. The main areas that he has been dealing with in the medical research world are aging and cancer treatment. He is focused on linking the two fields since cancer mostly affects old people who are past a certain age. Mikhail is determined to conduct research that will be beneficial to the oncology world. His success as a professor in the field has made him be an inspiration to his peers and students.The scientist attended First Pavlov State Medical University of St. Peterburg where he completed his master’s degree in internal medicine before enrolling for his Ph.D. in cardiology and experimental medicine at the institution. He was hired by the Valhalla-based New York Medical College in 2002 and later become a senior scientist at the Ordway Research Institute.

Mikhail worked at the organization until 2009 when he got a chance to serve Roswell Park Cancer Institute as a professor of oncology. The professor has developed an interest in researching about targeted cancer therapies that the prevent health human body cells from being damaged. He has also been studying the mechanism of aging and the development of anti-aging drugs. Mikhail has come up with a hypothesis that tries to explain the role of TOR signaling in cancer and aging. He has advised medical practitioners to use rapamycin in lengthening their cancer patients’ lives.he professor has also been involved in editorial undertakings. He acts as editor-in-chief of oncotarget, cell cycle, and aging. Mikhail is also a cancer biology and therapy associate editor and has been part of the cell death and differentiation editorial board. He has written hundreds of research papers, book chapters, and articles about cancer treatment. His work at the Rosewell Park Cancer Institute is greatly acknowledged.

Mikhail Blagosklonny And How He Runs Oncotarget

Mikhail Blagosklonny runs Oncotarget which is one of the largest and most-progressive medical journals in the world. This journal has been dedicated to ensuring the health and happiness of cancer patients for some time, and there are many people who benefit from the formatting and research content. This article explains why Oncotarget is such a wonderful addition to the libraries of many from the simplest of patient searches to doctor’s offices around the world.

#1: What Does Oncotarget Do?

Oncotarget was created to ensure that all patients would have access to new research in the field of cancer and coancer treatment. It is an online journal that anyone may access at any time, and it has quite a lot of information that is not found in other journals. Someone who wishes to look into this journal will find information on diagnosis, treatment and therapy for cancer patients, and they may use that information to help change their treatment plan or someone else’s.

#2: Who Submits Research?

The Oncotarget brand takes research every day from new writers, and they will publish anything that has passed thei review board. The review board that was created for the Oncotarget brand is rune xclusivelty by Mikhail Blagosklonny. There are many amazing professionals on this board, and they will look over every piece of research to ensure that they understand how it was created, if it has been done properly and what may be changed. They want each study to read well when it comes to them, and they are willing to offer feedback that makes it much easier for authors to change their approach.

#3: Who Benefits?

Anyone who has cancer or has been hit by cancer may read this unique journal. It is a place where the research has been compiled to ensure that cancer may be beaten, and someone who has questions about particular cancers may search the archives to find what they need. There are many people who are unsure of what to do about the diagnosis they have, and they may read some encouraging news about this diagnosis in the journal. This is a safe place for people to come when they have questions, and they may read through every edition of the journal if they have to.

#4: Remaining Cutting Edge

Oncotarget offers space for people to publish their research when they may not have the chance in other publications. The major medical journals are filled with many studies that are taking up space that could be used by others, and Oncotarget offers a bit of this space to all their readers. A chance is given to everyone who is new when they contact Oncotarget and Mikhail Blagosklonny.The Oncotarget journal is one that all cancer patients and family members should read. They have quite a lot of hope in the pages of each edition, and they will find that these studies have been reviewed and vetted as much as possible by the advisory board and their leader in Mikhail Blagosklonny.